The AAV vector market is advancing due to the rising demand for gene therapies targeting disease causes at the cellular level ...
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its off-the-shelf Rep/Cap plasmid offering, designed to streamline ...
JCR will present non-clinical data from its novel JUST-AAV gene therapy platform technology in an oral session at the ESGCT ...
Researchers have developed an engineered adeno-associated virus (AAV) vector that yields high transduction of brain vascular pericytes and smooth muscle cells. The study describing the ...
Groundbreaking study demonstrates that targeted oligodendrocyte gene therapy leads to decreased N-acetylaspartate (NAA) levels and increased ...
A mathematical model could help reduce the experimental effort needed to develop production processes for gene therapies. The digital twin, developed by a team at University College London (UCL) in ...
ProBio recently opened a gene therapy hub in a 128,000-square-foot facility in Mercer County, bringing more than 100 ...
Adeno-associated virus is an attractive vector for gene therapy as it is non-pathogenic and integrates into a specific site in the human genome. In the December 11 Early Edition of the Proceedings of ...
What Are AAV Vector-Based Therapies? Gene therapies are groundbreaking approaches utilizing viral and non-viral vectors. These vectors introduce therapeutic genes into patient cells to treat diseases, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback